Your browser doesn't support javascript.
loading
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais, Alice; Tauziède-Espariat, Arnault; Garcia, Jeremy; Appay, Romain; Uro-Coste, Emmanuelle; Meyronet, David; Maurage, Claude-Alain; Vandenbos, Fanny; Rigau, Valérie; Chiforeanu, Dan Christian; Pallud, Johan; Senova, Suhan; Saffroy, Raphaël; Colin, Carole; Edjlali, Myriam; Varlet, Pascale; Figarella-Branger, Dominique.
Afiliação
  • Métais A; GHU Psychiatrie et Neurosciences, Site Sainte-Anne, service de Neuropathologie, Paris, France.
  • Tauziède-Espariat A; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
  • Garcia J; GHU Psychiatrie et Neurosciences, Site Sainte-Anne, service de Neuropathologie, Paris, France.
  • Appay R; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
  • Uro-Coste E; APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
  • Meyronet D; APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
  • Maurage CA; Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.
  • Vandenbos F; Department of Pathology, Toulouse University Hospital, Toulouse, France.
  • Rigau V; Groupe Hospitalier Est, Département de Neuropathologie, Hospices Civils de Lyon, Bron, France.
  • Chiforeanu DC; Claude Bernard University Lyon 1, Lyon, France.
  • Pallud J; Department of Cancer cell plasticity - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
  • Senova S; Department of Pathology, Lille University Hospital, Lille, France.
  • Saffroy R; Department of Neuropathology, Hôpital Pasteur, Nice, France.
  • Colin C; Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
  • Edjlali M; Service d'Anatomie et Cytologie Pathologiques, Pontchaillou University Hospital, Rennes, France.
  • Varlet P; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
  • Figarella-Branger D; Department of Neurosurgery, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Acta Neuropathol Commun ; 11(1): 14, 2023 01 16.
Article em En | MEDLINE | ID: mdl-36647073
ABSTRACT

BACKGROUND:

Gliomas with FGFR3TACC3 fusion mainly occur in adults, display pathological features of glioblastomas (GB) and are usually classified as glioblastoma, IDH-wildtype. However, cases demonstrating pathological features of low-grade glioma (LGG) lead to difficulties in classification and clinical management. We report a series of 8 GB and 14 LGG with FGFR3TACC3 fusion in order to better characterize them.

METHODS:

Centralized pathological examination, search for TERT promoter mutation and DNA-methylation profiling were performed in all cases. Search for prognostic factors was done by the Kaplan-Meir method.

RESULTS:

TERT promoter mutation was recorded in all GB and 6/14 LGG. Among the 7 cases with a methylation score > 0.9 in the classifier (v12.5), 2 were classified as glioblastoma, 4 as ganglioglioma (GG) and 1 as dysembryoplastic neuroepithelial tumor (DNET). t-SNE analysis showed that the 22 cases clustered into three groups one included 12 cases close to glioblastoma, IDH-wildtype methylation class (MC), 5 cases each clustered with GG or DNET MC but none with PLNTY MC. Unsupervised clustering analysis revealed four groups, two of them being clearly distinct 5 cases shared age (< 40), pathological features of LGG, lack of TERT promoter mutation, FGFR3(Exon 17)TACC3(Exon 10) fusion type and LGG MC. In contrast, 4 cases shared age (> 40), pathological features of glioblastoma, and were TERT-mutated. Relevant factors associated with a better prognosis were age < 40 and lack of TERT promoter mutation.

CONCLUSION:

Among gliomas with FGFR3TACC3 fusion, age, TERT promoter mutation, pathological features, DNA-methylation profiling and fusion subtype are of interest to determine patients' risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Ganglioglioma / Glioblastoma / Glioma Tipo de estudo: Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Ganglioglioma / Glioblastoma / Glioma Tipo de estudo: Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article